NCT00048906View on ClinicalTrials.gov

Alpha-Galactosidase A Replacement Therapy for Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

November 30, 2003

Conditions
Fabry Disease
Interventions
DRUG

DRX005B

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00048906 - Alpha-Galactosidase A Replacement Therapy for Fabry Disease | Biotech Hunter | Biotech Hunter